<DOC>
	<DOCNO>NCT01192997</DOCNO>
	<brief_summary>There evidence wan immunity individual vaccinate meningitis C part UK infant immunisation schedule . The intention study contact participant previous NVEC ( National Vaccine Evalutaion Consortium ) clinical trial ( PreSchool Men C trial , participant randomise receive Meningitec , Menjugate Neisvac-C ) . They invite enrol randomise receive one two quadrivalent meningococcal ACWY vaccine , look boost effect may confer .</brief_summary>
	<brief_title>Comparison Two Meningococcal ACWY Conjugate Vaccines</brief_title>
	<detailed_description>Between 550 650 subject enrol previous Meningococcal C vaccine study invite join new study look boost effect two quadrivalent meningococcal ACWY vaccine . If choose participate , randomise receive one ACWY vaccine . Within vaccine group , division short ( 6 month ) long ( 9 month ) follow-up . Each participant give one dose allocate vaccine . Blood sample take three time participant - first sample pre-vaccination ; second sample take one month vaccination ; third final sample either six nine month vaccination ( depend group randomise ) .</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis , Meningococcal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Previously enrol Preschool Men C study conduct NVEC 1999/2000 Participant 's parent legally authorize representative willing able give write informed consent participation nature study explain . No contraindication vaccination specify `` Green Book '' Immunisation Infectious Disease , HMSO . Participant give assent participation study . Vaccinated Meningitec ( MCC CRM ) Menjugate ( MCC CRM ) NeisVacC ( MCC TT ) 3.56 year age . Known free medical problem determine medical history clinical assessment . Parent legally authorise representative willing allow child 's GP notify participation study contact require confirmation vaccination history . History invasive meningococcal disease . Have history household contact intimate exposure individual culture prove Neisseria meningitis disease previous 60 day . Any vaccination MenC disease since MCC vaccine give 3.5 6 year . Participant pregnant . Confirmed suspect immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection . Major congenital defect serious chronic disease include progressive neurological disease seizure disorder . Have know bleeding diathesis , condition may associate prolonged bleeding time . Have history severe allergic reaction previous vaccination anaphylactic shock , asthma , urticaria , allergic reaction hypersensitivity vaccine component . Have receive another investigational agent within 90 day completion safety followup period another study , whichever longer , prior enrollment unwilling refuse participation another investigational trial end study . In event administration another license vaccine need study , vaccine administer within 30 day study injection accord investigator 's judgment ( exception : licensed fluvaccine administer within 14 day study vaccine ) . Have receive blood blood product within past 12 week . Have significant disease disorder , opinion investigator , may either put participant risk participation study , may influence result study , participant 's ability participate study . Temporary Exclusion Criteria â€¢ Receipt systemic antibiotic ( either oral parenteral ) delay enrolment least 7 day cessation antibiotic .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Meningitis</keyword>
	<keyword>Meningococci</keyword>
	<keyword>Meningitis C</keyword>
	<keyword>Meningitis A</keyword>
	<keyword>Meningitis W135</keyword>
	<keyword>Meningitis Y</keyword>
	<keyword>Antibody</keyword>
</DOC>